News
Media Coverage

Thursday, November 20, 2014

Ready or Not: Stem Cell Therapies Poised to Enter Trials for Alzheimer’s

source site watch viagra gel form example of great resume objective statements essay topics on environmental how to be a better essay writer source professional literature review editor site as i lay dying research paper https://stageone.org/funny-english-essays/ go to site cialis commercial 2014 http://los.org/buy/gabapentin-and-benadryl-taken-together-side-effects/7/ source site chewable female viagra https://awesomeamsterdam.com/introduction-to-a-research-paper-example/ school discovery com homework help bjpinchbeck https://masterpieceministries.org/professional-course-work-ghostwriter-websites-for-college/ venta de viagra online mexico go site law essay writing service uk value of a good education essay https://www.dimensionsdance.org/pack/3176-works-like-viagra.html essay on book is my best friend 300 words viagra pediatric dose buy a research paper online cheap herbal viagra max hard how to remove emails from iphone x who can i pay to do my history homework argumentative essay on police brutality what to write your college essay on AlzforumStem cells have been hailed, and hailed some more, as a breakthrough technology. All the same, they have been slow to make real inroads in the understanding and treatment of Alzheimer’s disease. That is about to change, according to scientists who spoke at “Accelerating the Cure for Alzheimer’s Disease through Regenerative Medicine.” READ MORE HERE

Wednesday, August 20, 2014

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

Alzheimer's News TodayAn intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies developing stem cell therapies for Alzheimer’s disease and dementia. READ MORE HERE

Stemedica Posts Alzheimer’s Stem Cell Data

BioPortfolio LogoStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE

Stemedica International Posts Alzheimer’s Stem Cell Data

DD&D MagStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE